Browse 1,513 myasthenia gravis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Myasthenia gravis causes muscle weakness that gets worse with use and improves with rest, often starting with a drooping eyelid or double vision. For decades treatment relied mainly on steroids and broad immune suppression, with side effects that can be hard to live with. In recent years several new targeted medicines have been approved that act directly on the antibodies behind the disease.
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
Location: Boston MA, Bethesda MD, Toronto, Pittsburgh PA,
Sponsor: Ankyra Therapeutics, Inc
Sex: All
Age: 18+
Code: NCT06171750
Phase 1, Recruiting
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
for
Advanced Cancer, Gastric Cancer, Breast Cancer,
Location: Winston-Salem NC, Birmingham AL, Scottsdale AZ,
Sponsor: Minneamrita Therapeutics LLC
Sex: All
Age: 18+
Code: NCT03129139
Phase 1, Recruiting
A Study of PYX-201 in Advanced Solid Tumors
for
Solid Tumor, Advanced Solid Tumor
Location: Boston MA, Providence RI, New York NY, Philadelphia PA,
Sponsor: Pyxis Oncology, Inc
Sex: All
Age: 18+
Code: NCT05720117
Phase 1, Recruiting
Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
for
Nervous System Disease, Immune System Disease
Location: Bethesda MD
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 2 - 70+
Code: NCT06169150
Recruiting
Imaging of Solid Tumors Using FAP-2286
for
Solid Tumors, Adult, Metastatic Cancer
Location: San Francisco CA
Sponsor: Thomas Hope
Sex: All
Age: 18+
Code: NCT04621435
Phase 1, Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors